US · Healthcare · Diagnostics & Research
EPS came in at 1.41 against a street estimate of 1.23 — a beat of 14.6%.
Analysts rate Revvity Inc. a buy (12 buy, 7 hold, 0 sell out of 19) with an average price target of $126.12.
CONFIDENT Revvity beat Q2 expectations with 3% organic growth and raised full-year guidance. Diagnostics surged 11%; Life Sciences soft due to software comps but instrument backlog strong. AI-driven drug discovery is creating new demand; tariff refunds provided $0.08 of upside. Q2 2026 Software and latent TB pressures weighed on Americas; Europe's strength offset regional weakness. Analysts pressed for backlog sizing, tariff benefit quantification, and AI customer identity. Management largely deferred on backlog magnitude and AI opportunity scale, citing early innings. Emphasized operational beat and guidance lever came from organic growth, not one-time items alone. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 19.89% |
| T. Rowe Price Associates, Inc. | 9.04% |
| EdgePoint Investment | 7.66% |
| HHG PLC | 7.48% |
| Vanguard Capital Management, LLC | 6.57% |
| BlackRock Inc | 6.50% |
| Vanguard Portfolio Management, LLC | 4.31% |
| State Street Corp | 3.86% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 REVVITY, INC. – FORM 10-Q SUMMARY Quarter Ended July 5, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months): $1,440,806k ($1,184,869k product + $2 | 2026-08-11 |
| Results announced · Q3 2026 REVVITY INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $730 million (reported); $711 million pro forma vs. $681 million pro for | 2026-08-04 |
| Quarterly report · Q2 2026 REVVITY, INC. - Q1 2026 (10-Q) SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Total Revenue (Q1 2026): $711.1 million, up from $664.8 million | 2026-05-12 |
| Results announced · Q2 2026 REVVITY Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $711 million (reported); $687 million (pro forma), up 7% year-over-yea | 2026-05-05 |
| Charter / bylaws change · Q2 2026 REVVITY, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholder Meeting Date: April 28, 2026 • Company: Revvity, Inc., Massachusetts-based, ticker | 2026-05-01 |
| Proxy statement · Q2 2026 REVVITY, INC. – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION • Prahlad R. Singh (President and CEO) total compensation: Document does not state the | 2026-03-16 |
| Annual report FY2025 REVVITY, INC. – FORM 10-K SUMMARY (FISCAL YEAR ENDED DECEMBER 28, 2025) HEADLINE NUMBERS • Stock listing: Common stock trades on NYSE under symbol R | 2026-02-24 |
| Results announced · Q1 2026 REVVITY, INC. – Q4 2025 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 2025 Revenue: $772 million (6% growth year-over-year; 4% organic growth) • Q4 2025 GA | 2026-02-02 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.07 / share ex-date Oct 23, 2026 · pay Nov 13, 2026 | 2026-10-23 |
| Dividend | $0.07 / share ex-date Jul 17, 2026 · pay Aug 7, 2026 | 2026-07-17 |
| Dividend | $0.07 / share ex-date Apr 17, 2026 · pay May 8, 2026 | 2026-04-17 |
| Dividend | $0.07 / share ex-date Jan 16, 2026 · pay Feb 6, 2026 | 2026-01-16 |
| Dividend | $0.07 / share ex-date Oct 17, 2025 · pay Nov 7, 2025 | 2025-10-17 |
| Announcement | Date |
|---|---|
| Definitive agreement signed to sell China Immunodiagnostics business assets Revvity, Inc. announced Q2 2026 financial results on August 4, 2026, and disclosed a major business restructuring. The company signed a definitive agreement on July 31, 2026, to sell substan | 2026-08-04 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Revvity Inc. — free to start.
Google PlayApp StoreData updated 2026-09-18.